Clinical trials
Metastatic Tumor clinical trials
Below are recruiting metastatic tumor clinical trials, each written for real people, not researchers. We’re tracking 583 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06967961Recruiting
Looking for cancer cells that carry two markers in the blood
This trial is studying a special type of cell that shows up in the blood of people with certain advanced cancers. It aims to find out if these cells can help doctors better understand the cancer and guide treatment.
ToulouseAges 18 years+ - NCT07661771RecruitingPhase 3
Personalized radiation therapy for nasopharyngeal cancer
This trial tests a new way to plan radiation treatment for nasopharyngeal cancer, where the target area is tailored to each patient's tumor spread. It aims to improve effectiveness while reducing side effects.
Dongguan, GuangdongAges 18–65 - NCT02621021RecruitingPhase 2
Immune cell therapy for advanced melanoma
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
Bethesda, MarylandAges 18–72 - NCT06690528RecruitingPhase 2
Surgery vs. palliative care for pancreatic cancer with limited liver spread
This trial compares surgery to remove the primary tumor and up to 3 liver spots against standard palliative care for people with pancreatic cancer that has spread only to the liver (up to 3 spots). It is for those whose cancer has not grown after initial chemotherapy and who are healthy enough for surgery.
Padova, ItalyAges 18–75 - NCT07223411Recruiting
Opdualag vs. cemiplimab/fianlimab for melanoma
This trial compares two treatments for advanced melanoma that cannot be removed with surgery or has spread. It studies how these treatments affect the immune response in tumors and blood, and requires extra biopsies and blood draws.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06473961RecruitingPhase 1
GC101 cell therapy for advanced non-small cell lung cancer
This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.
ShanghaiAges 18–70 - NCT05443087Recruiting
Checking blood levels of targeted drugs for digestive cancers
This trial monitors how your prescribed targeted cancer medicine moves through your body by doing extra blood tests. The goal is to understand the drug’s levels and dosing in people with advanced digestive cancers, so treatment can be better managed.
AmiensAges 18 years+ - NCT06222879RecruitingPhase 1/Phase 2
New drug combinations for advanced breast cancer
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
Changsha, HunanAges 18–75 - NCT06333314RecruitingPhase 2
Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
AngersAges 18 years+ - NCT06821048RecruitingPhase 1
CAR-T cells targeting CEA for advanced solid tumors
This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.
Hangzhou, ZhejiangAges 18 years+ - NCT07282912RecruitingPhase 2
Extra treatment for certain digestive cancers with undetectable ctDNA
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
New Haven, ConnecticutAges 18–80 - NCT07339085Recruiting
Advanced MRI for brain tumor recurrence or radiation damage
This study uses advanced MRI scans to better tell the difference between a returning brain tumor and radiation injury. It may help guide your treatment decisions.
Los Angeles, CaliforniaAges 18 years+ - NCT06805812Recruiting
Predicting outcomes of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
AvianoAges 18 years+ - NCT06503783RecruitingPhase 1
Study of BL-M17D1 for advanced breast cancer and solid tumors
This trial tests a new drug, BL-M17D1, for people with advanced breast cancer (HER2 positive or negative) or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Harbin, HeilongjiangAges 18–75 - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+ - NCT06680596Enrolling by invitationPhase 2
Blood test to find T-DXd candidates for breast cancer
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
AmiensAges 18 years+ - NCT05327010RecruitingPhase 2
Testing a new drug combination for advanced solid tumors
This trial is studying whether a new combination of two cancer drugs, ZEN003694 and talazoparib, can help people with advanced solid tumors that have not responded to other treatments. Talazoparib is a type of drug that targets cancer cells with certain DNA repair problems. The study is divided into groups based on specific gene mutations or previous treatment responses.
Duarte, CaliforniaAges 18 years+ - NCT06155084RecruitingPhase 1/Phase 2
HP518 for advanced prostate cancer that has spread
This trial tests an oral drug called HP518 for men with a specific genetic change in their prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. The goal is to see if HP518 can control the cancer.
Hefei, AnhuiAges 18 years+ - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07003321RecruitingPhase 2
Testing HRS-4508 for advanced non-small cell lung cancer
This trial tests an experimental drug called HRS-4508 for people with advanced non-small cell lung cancer that has stopped responding to standard treatments or cannot tolerate them. The goal is to see if it can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07394374RecruitingPhase 1/Phase 2
CG001419 Tablets for Advanced Solid Tumors with NTRK Changes
This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.
BeijingAges 18 years+ - NCT05687110RecruitingPhase 1
Testing novobiocin for tumors with DNA repair gene changes
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
Duarte, CaliforniaAges 18 years+ - NCT05994170Recruiting
Lower radiation dose to tumor area for early nasopharyngeal cancer
This trial studies whether lowering the radiation dose to a smaller area around the tumor is safe and effective for people with newly diagnosed nasopharyngeal cancer that has not spread. It may reduce side effects while still curing the cancer.
Zhongshan, GuangdongAges 18–70 - NCT06010875RecruitingPhase 1
CD70-targeted CAR-T cell therapy for advanced solid tumors
This trial tests a new treatment using your own immune cells (CAR-T cells) designed to attack cancer cells that have a protein called CD70. It is for people with advanced solid tumors that have not responded to standard treatments.
Nanchang, JiangxiAges 18 years+
Hear when a new Metastatic Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic tumor?
- Yes. Clin2 currently lists 583 recruiting metastatic tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.